Dr Harpole on Perioperative Durvalumab Plus Chemotherapy in EGFR-Mutated NSCLC

David Harpole, MD, discusses findings from an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer.

Related Keywords

David Harpole ,Duke Cancer Institute ,George Barth Geller Distinguished Professor For Research ,George Barth Geller Distinguished Professor ,D ,Aegean Trial ,Nct03800134 ,Patients With Egfr Mutated Non Small Cell Lung Cancer ,